Interim Report First Quarter 2020

STENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2020 – 31.03.2020. The report is available on

Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments: “Financially, the Q1-20 result was expected because of our pause in sales of products. We run a lean and agile operation that has been adapted to handle the current situation. In February, STENOCARE was honoured to be identified as a European leader in medical cannabis and a company to watch by the leading medical cannabis analyst’ Prohibition Partners. Adding to this encouraging news, Q1-20 also marked the beginning of the end of the temporary pause in sales (since July-19) of our branded products to patients in Denmark and beyond. Products from our new supplier Panaxia are now undergoing the process of being approved for the market. That is a good feeling. Last, but not least, I am pleased to confirm that – despite recent covid19 turbulence – STENOCARE remains very much intact, determined and ambitious about our business. We have cash in the bank and a Danish market that is impatiently awaiting the reintroduction of our products. With our ambitious STENOCARE 2.0 strategy, that is designed to convert our early market leadership into real international leadership in the European medical cannabis industry, we think we are in a strong position to capture the growth opportunity that is in front of us.”

(KDKK) 01.01.202031.03.20203 months 01.01.201931.03.20193 months 01.01.201931.12.201912 months 01.01.201831.12.201812 months
Total income *) 93 4,317 16,206 4,145
Net sales 93 4,317 4,942 4,145
Operating profit before depreciation (EBITDA) -2,626 1,525 4,417 -3,591
Net financial items -917 6 -2,112 -13
Result per share (DKK) -0.32 0.13 0.19 -0.47
Solidity (%) 38 91 43 94

Result per share: The result for the period divided by the average number of shares. Total number of shares as of March 31st 2020, amounted to 8,942,762 (8,942,762). Average number of shares for the first quarter 2020 is 8,942,762 (8,942,762).

Solidity: Equity divided by total capital.

*Total income incl. net sales and other income.

Highlights during the period


This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on May 7th, 2020.


For additional information regarding STENOCARE, please contact:

Thomas Skovlund Schnegelsberg, CEO

Phone: +45 31770060



STENOCARE A/S was founded in 2017 with the purpose of being an active participant in the Danish medical cannabis pilot program. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. The company offers medical cannabis oil that complies with the strict Danish regulatory requirements. STENOCARE is building a state-of-the-art production facility for the cultivation and production of medical cannabis at the company’s premises in Jutland, Denmark. 


Interim Report Q1-2020 - STENOCARE.pdf